FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lenkowsky Adam		 2. Date of Event Requiring Statement (MM/DD/YYYY)
4/26/2023 

 3. Issuer Name and Ticker or Trading Symbol

BRISTOL MYERS SQUIBB CO [BMY]
(Last)        (First)        (Middle)

430 E. 29TH STREET, 14TH FLOOR		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
EVP, Chief Commercial Officer /
(Street)

NEW YORK, NY 10016      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $0.10 par value 5148.628 (1)I BMS Savings and Investment Program 
Common Stock, $0.10 par value 4899.769 I By Spouse 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units  (2)6/3/2023 Common Stock, $0.10 par value 1077.0  (3)D  
Market Share Units  (4)3/10/2024 Common Stock, $0.10 par value 1698.0  (5)D  
Market Share Units  (6)3/10/2025 Common Stock, $0.10 par value 3806.0  (5)D  
Market Share Units  (7)3/10/2026 Common Stock, $0.10 par value 5478.0  (8)D  
Market Share Units  (9)3/10/2027 Common Stock, $0.10 par value 8001.0  (8)D  
Performance Shares  (10)3/10/2024 Common Stock, $0.10 par value 11416.0  (10)D  
Performance Shares  (11)3/10/2025 Common Stock, $0.10 par value 10955.0  (11)D  
Performance Shares  (12)3/10/2026 Common Stock, $0.10 par value 12002.0  (12)D  
Market Share Units  (13) (13)Common Stock, $0.10 par value 1802.0  (14)I By Spouse 
Performance Shares  (15) (15)Common Stock, $0.10 par value 3580.0  (15)I By Spouse 
Explanation of Responses:
(1) Based on recent 401(k) plan statement.
(2) These restricted stock units will vest on June 3, 2023.
(3) Each restricted stock unit converts into one share of common stock upon vesting.
(4) These market share units will vest on March 10, 2024.
(5) Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%.
(6) One-half of these market share units will vest on each of March 10, 2024 and March 10, 2025.
(7) One-third of these market share units will vest on each of March 10, 2024, March 10, 2025, and March 10, 2026.
(8) Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%.
(9) Twenty-five percent of these market share units will vest on each of the first, second, third, and fourth anniversaries of the grant date, starting on March 10, 2024.
(10) Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2024.
(11) Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2025.
(12) Each performance share unit converts into one share of common stock upon distribution in the first quarter of 2026.
(13) These market share units ("MSUs"), held by the reporting person's spouse, include 925 MSUs that will vest on March 10, 2024, 597 on March 10, 2025, and 280 on March 10, 2026.
(14) Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). For MSUs vesting on March 10, 2024 and March 10, 2025, the minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. For MSUs vesting on March 10, 2026, the minimum payout factor that must be achieved to earn a payout of 80% and the maximum payout of 225%.
(15) These performance share units ("PSUs"), held by the reporting person's spouse, include 1,909 PSUs that will vest on March 10, 2024, and 1,671 on March 10, 2025.

Remarks:
EXHIBIT LIST: EX-24 Exhibit 24 - Adam Lenkowsky, GRAPHIC Exhibit 24 - Adam Lenkowsky

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Lenkowsky Adam
430 E. 29TH STREET
14TH FLOOR
NEW YORK, NY 10016

EVP, Chief Commercial Officer
Signatures
/s/ Lisa A. Atkins, attorney-in-fact for Adam Lenkowsky5/3/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Bristol Myers Squibb (PK) (USOTC:BMYMP)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Bristol Myers Squibb (PK).
Bristol Myers Squibb (PK) (USOTC:BMYMP)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Bristol Myers Squibb (PK).